Effects of angiogenic growth factor combinations on retinal endothelial cells.

The aim of this paper was to determine if growth factors, known to be upregulated in proliferative diabetic retinopathy, exerted combined effects on retinal endothelial cells. The authors explored the individual and collective actions of insulin-like growth factor I (IGF-I), vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), fibroblast growth factor-2 (FGF-2) and placenta growth factor (PlGF) on several parameters that reflect the angiogenic potential of endothelial cells. The effect of growth factors on cell migration and survival/proliferation was examined using primary cultures of bovine retinal endothelial cells (BREC). The authors also determined the growth factor action on capillary-like tube formation on a reconstituted basement membrane matrix and on the newly described phenomenon of secondary sprouting, in which endothelial cell colonies spontaneously survive, proliferate, migrate and invade the matrix after the original capillary-like tubes have collapsed. Sprouting cells were positive for von Willebrand factor and could aggregate into larger tubes with lumens. Incubation with VEGF+IGF-I or PlGF+FGF-2 enhanced tube stability by 40-50%, more than each growth factor alone or other combinations (5-20%). The concurrent addition of four growth factors did not improve the response seen with growth factor pairs. Surprisingly, PDGF-BB induced tube collapse. IGF-I and FGF-2 mildly enhanced BREC proliferation/survival (5-15%). However, VEGF+IGF-I or PlGF+FGF-2 increased BREC proliferation/survival by 25% under low serum conditions, whereas combinations of all four growth factors exerted a clearly synergistic effect (250% increase). PDGF-BB or FGF-2 stimulated secondary sprouting and were the only factors capable of exerting this effect alone. Even though VEGF, IGF-I or PlGF were not effective, if administered in pairs, they demonstrated increased responses. PDGF-BB was also able to enhance the effect of FGF-2+IGF-I+VEGF on BREC secondary sprouting, but not of any of them individually. No other growth factor tested was able to significantly improve the action of combinations of three other growth factors. VEGF increased cell migration in a wounded monolayer assay two-fold and PDGF-BB, 2.5 times, but other individual growth factors were ineffective. PlGF+FGF-2 enhanced cell migration more than each factor alone. VEGF+IGF-I+PlGF+FGF-2, however, increased cell migration four-fold. In summary, this study indicates that growth factors, overexpressed in diabetic retinopathy eyes, enhance the angiogenic characteristics of cultured cells (tube formation, proliferation, secondary sprouting and migration). Their effects, however, can be greatly augmented by other growth factors that alone exert little or no action. Therefore, diabetic retinal neovascularization may result from the additive or synergistic action of several growth factors.

[1]  A. Albini,et al.  In Vitro Models of Angiogenesis: The use of Matrigel , 1999, The International journal of biological markers.

[2]  P Massin,et al.  Growth factors and diabetic retinopathy. , 1997, Diabetes & metabolism.

[3]  P. Maher,et al.  Inhibition of Cell Migration by 24-kDa Fibroblast Growth Factor-2 Is Dependent upon the Estrogen Receptor* , 2001, The Journal of Biological Chemistry.

[4]  F. Luyten,et al.  Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. , 1992, Experimental cell research.

[5]  P. Campochiaro,et al.  Retinal and choroidal neovascularization , 2000, Journal of cellular physiology.

[6]  H. Granger,et al.  Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[7]  J. McCarthy,et al.  Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. , 1996, The Biochemical journal.

[8]  M. Boulton,et al.  Increased expression of placenta growth factor in proliferative diabetic retinopathy. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[9]  N. Morisaki,et al.  Migratory and proliferative effect of platelet‐derived growth factor in rabbit retinal endothelial cells: Evidence of an autocrine pathway of platelet‐derived growth factor , 1994, Journal of cellular physiology.

[10]  Andrius Kazlauskas,et al.  Growth-factor-dependent mitogenesis requires two distinct phases of signalling , 2001, Nature Cell Biology.

[11]  M. Grant,et al.  Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. , 1991, Investigative ophthalmology & visual science.

[12]  Y. Hata,et al.  Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. , 1995, Ophthalmic research.

[13]  Joan W. Miller,et al.  Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. , 1994, American journal of ophthalmology.

[14]  F. Malecaze,et al.  Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. , 1994, Investigative ophthalmology & visual science.

[15]  Hidehiro Ishii,et al.  Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor , 1997, Diabetes.

[16]  Lois E. H. Smith,et al.  Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor , 1999, Nature Medicine.

[17]  L. Aiello,et al.  Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. , 1998, Ophthalmic research.

[18]  J. Folkman,et al.  In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. , 1996, The Journal of clinical investigation.

[19]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[20]  L. Jarett,et al.  Characterization of the growth of murine fibroblasts that express human insulin receptors. II. Interaction of insulin with other growth factors. , 1990, Experimental cell research.

[21]  L. Mandarino.  Current Hypotheses for the Biochemical Basis of Diabetic Retinopathy , 1992, Diabetes Care.

[22]  G. Conn,et al.  Purification and Characterization of a Naturally Occurring Vascular Endothelial Growth Factor · Placenta Growth Factor Heterodimer (*) , 1995, The Journal of Biological Chemistry.

[23]  L. Aiello,et al.  Molecular mechanisms of growth factor action in diabetic retinopathy , 1999 .

[24]  G. Laurie,et al.  Basement membrane complexes with biological activity. , 1986, Biochemistry.

[25]  E. Farber,et al.  Nerve growth factor increases the mitogenicity of certain growth factors for cultured human keratinocytes: A comparison with epidermal growth factor , 1994, Experimental dermatology.

[26]  E. De Clercq,et al.  Angiogenesis: regulators and clinical applications. , 2001, Biochemical pharmacology.

[27]  M. Grant,et al.  Insulin-Like Growth Factors in Vitreous: Studies in Control and Diabetic Subjects with Neovascularization , 1986, Diabetes.

[28]  F. Bayard,et al.  Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy. , 1996, Diabetes & metabolism.

[29]  J. Folkman,et al.  Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[30]  A Mathis,et al.  Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. , 1994, Archives of ophthalmology.

[31]  J. Flanagan,et al.  Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.

[32]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[33]  L. Naumovski,et al.  Endothelial cell apoptosis in capillary network remodeling , 1999, Journal of cellular physiology.

[34]  J. Ward,et al.  IGF-I increases bFGF-induced mitogenesis and upregulates FGFR-1 in rabbit vascular smooth muscle cells. , 1996, The American journal of physiology.

[35]  E S Gragoudas,et al.  Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.

[36]  S. Butterwith,et al.  Regulation of adipocyte precursor DNA synthesis by acidic and basic fibroblast growth factors: interaction with heparin and other growth factors. , 1993, The Journal of endocrinology.

[37]  S. Gammeltoft,et al.  Insulin-like growth factors act synergistically with basic fibroblast growth factor and nerve growth factor to promote chromaffin cell proliferation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Simó,et al.  Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. , 2000, Diabetes care.

[39]  L. Aiello,et al.  Diabetic eye disease. , 1996, Endocrinology and metabolism clinics of North America.

[40]  L. Aiello,et al.  Role of vascular endothelial growth factor in diabetic vascular complications. , 2000, Kidney international. Supplement.

[41]  Lois E. H. Smith,et al.  Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Brown,et al.  Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. , 1990, Archives of ophthalmology.

[43]  L. Liotta,et al.  Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. , 1982, Biochemistry.

[44]  L. Aiello,et al.  Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. , 1999, Diabetes.

[45]  J. Spranger,et al.  Growth Factor Alterations in Advanced Diabetic Retinopathy: A Possible Role of Blood Retina Barrier Breakdown , 1997, Diabetes.

[46]  S. Baatout.  Endothelial differentiation using Matrigel (review). , 1997, Anticancer research.

[47]  L. Orci,et al.  Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. , 1992, Biochemical and biophysical research communications.

[48]  G. Werther,et al.  Interactions between growth hormone, insulin-like growth factor I, and basic fibroblast growth factor in melanocyte growth. , 1999, The Journal of clinical endocrinology and metabolism.

[49]  P. Campochiaro,et al.  Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. , 2000, The American journal of pathology.

[50]  P. Wiedemann,et al.  Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR) , 1997, International Ophthalmology.

[51]  J. Tarbell,et al.  Kinetics of placenta growth factor/vascular endothelial growth factor synergy in endothelial hydraulic conductivity and proliferation. , 2001, Microvascular research.

[52]  L. P. Aiello.  Vascular endothelial growth factor. 20th-century mechanisms, 21st-century therapies. , 1997, Investigative ophthalmology & visual science.

[53]  P. Dell’Era,et al.  Examining new models for the study of autocrine and paracrine mechanisms of angiogenesis through FGF2-transfected endothelial and tumour cells. , 2000, Advances in experimental medicine and biology.

[54]  A. Schor,et al.  Collagen gel assay for angiogenesis : induction of endothelial cell sprouting. , 2001, Methods in molecular medicine.

[55]  S. Hagan,et al.  Hepatocyte growth factor/Scatter factor in the eye , 2000, Progress in Retinal and Eye Research.

[56]  K. Sandau,et al.  Automated evaluation of angiogenic effects mediated by VEGF and PlGF homo- and heterodimers. , 1998, Microvascular research.

[57]  M. Boulton,et al.  Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management , 1997, The British journal of ophthalmology.

[58]  M. Derwahl,et al.  Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[59]  R. Simó,et al.  Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy , 2000, The British journal of ophthalmology.

[60]  A. Ljubimov,et al.  Basement membrane and growth factor gene expression in normal and diabetic human retinas. , 1999, Current eye research.

[61]  M. Grant,et al.  Neovascular growth factors , 1991, Eye.

[62]  J. Robertson,et al.  Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. , 1994, Investigative ophthalmology & visual science.

[63]  A. Ljubimov,et al.  Distribution of individual components of basement membrane in human colon polyps and adenocarcinomas as revealed by monoclonal antibodies , 1992, International journal of cancer.

[64]  C. Bucana,et al.  Regulation of distinct steps of angiogenesis by different angiogenic molecules. , 1998, International journal of oncology.